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Introduction
Most non-Hodgkin’s Lymphomas (NHL) arise in 
lymph nodes or other lymphatic tissues such as the spleen, 
Waldeyer’s ring and thymus. However, a substantial 
percentage of NHL arises from tissues other than lymph 
nodes and even from sites, which normally contain no 
lymphoid tissue. These forms are referred to as primary 
extranodal lymphomas (pENL). Approximately 25-40 % 
of NHL arises primarily from sites other than lymph nodes 
(d’Amore et al., 1991; Freeman et al., 1972; Otter et al., 
1989; Newton et al., 1997; Padhi et al., 2012).
The definition of pENL, particularly in the presence of 
both nodal and extranodal disease, remains a controversial 
issue. Different criteria have been proposed by various 
authors in the past, to categorize these entities (Dawson 
et al., 1961; Krol et al., 2003). As per Dowson criteria, 
lymphoma is said to be primarily extranodal in 1) absence 
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 Background: The aim of this study was to assess the epidemiological and clinicopathological characteristics 
of primary extranodal non-Hodgkin’s lymphoma (pENL) patients, focusing on treatment and survival outcome. 
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in stage III, whereas 6/100 (6%) were in stage IV. Head and neck constituted the most common site (51/100, 
51%), followed by gastrointestinal tract (GIL) (37/100, 37%), and cerebrum (CL) (5/100, 5%). Diffuse large 
B cell lymphoma (DLBCL) was the most common histological type, observed in 53% of patients, followed by 
marginal zone extranodal lymphoma (13%). Most of patients (76%) received a CHOP containing regimen. 
Complete remission (CR) were achieved in 71% of patients. The median follow-up duration of all patients 
was reported as 37.6 months (range, 0.8-165 months). This period was reported as 137.5 months (range, 117.5-
1578.6 months) in gastrointestinal lymphoma (GIL) patients, 119.0 months (range, 91.8-146.1 months) in head 
and neck lymphoma (HNL) patients, and 18.4 months (range, 12.6-24.1 months) in cerebral lymphoma (CL) 
patients. Conclusions: Head and neck, and the gastrointestinal tract were the two most common extranodal 
sites observed. Histologically DLBC accounted for the majority of cases. Most patients were on earlier stages, 
had low-low intermediate IPI scores and had a favorable prognosis. 
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of palpable superficial lymph nodes on first physical 
examination; 2) absence of mediastinal lymphadenopathy 
detected on plain chest x-ray; 3) dominant lesion at 
extranodal sites; 4) involvement of lymph nodes in the 
vicinity of the primary lesion; 5) white blood cell (WBC) 
count within normal range.
The incidence of extranodal NHL in western countries 
has increased substantially in the last 40 years (Groves 
et al., 2000; Chiu et al., 2003). This may partly be due to 
improved diagnostic procedures (particularly in brain and 
gastrointestinal lymphomas) and changes in classification 
systems, but much of the changes are real and the AIDS 
epidemic in the 1980’s does not completely explain this 
rise (Groves et al., 2000).
The etiology of ENL’s appears to be multifactorial 
and includes immune suppression, infections both viral 
and bacterial, and exposure to pesticides and other 
environmental agents.
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The aim of this study was to assess the epidemiological 
and clinicopathological characteristics of pENL patients, 
focusing on treatment and survival outcome.
Materials and Methods
Between October 2003 and March 2012, 802 
patients with NHL were diagnosed and treated in two 
different centers (Mersin University, School of Medicine, 
Department of Medical Oncology and Baskent University 
School of Medicine, Department of Medical Oncology).
Data pertaining to patients’ demography, clinical 
presentation, routine complete blood count (CBC), 
microbiological (HIV, HCV, and Hepatitis B status) and 
biochemical parameters [Serum total protein, serum 
albumin, serum urea, creatinine, uric acid, lactate 
dehydrogenase (LDH) bilirubin and liver enzymes] were 
obtained from medical records. Clinical stage was defined 
according to the Ann Arbor classification (Carbone et al., 
1971).
Staging was performed according to results of physical 
examination; surgical reports; computed tomography scan 
of the thorax, abdomen, and pelvis; positron emission 
tomography; and bone marrow biopsy. Where indicated, a 
bone scan, biopsies of suspicious lesions, and examination 
of the cerebrospinal fluid were also performed.
Lymphomas that presented in extranodal organs with 
no or minor lymph node involvement were considered 
primary extranodal, whereas lymphomas with clinically 
dominant  lymph node involvement were considered as 
primary nodal. Waldeyer’s ring and spleen were considered 
as nodal sites. The bone marrow was considered as an 
extranodal site.
All 100 patients were histopathologically detected as 
NHL. The diagnosis of NHL and its subtype was based 
on the criteria established in World Health Organization 
(WHO) classification for all cases. Immunohistochemical 
(IHC) analyses were performed manually on the paraffin-
embedded tissue sections by using a panel of monoclonal 
antibodies (Peroxidase-anti peroxidase method). The panel 
included CD45, CD20, CD3, CD15, CD30, CD5, bcl 2, 
cyclin D1, and anaplastic large cell lymphomakinase-1 
(ALK).
The International Prognostic Index (IPI) was 
calculated according to the description by the international 
non-Hodgkin’s Prognostic Factors Project for patients 
with all required parameters present.
Patients with CD20+, intermediate or high grade 
lymphoma received CHOP plus Rituximab which 
consisted of intravenous cyclophosphamide (750mg/
m2), intravenous doxorubicin (50 mg/m2), intravenous 
vincristine (1.4 mg/m2, maximum daily dose of 2 mg), 
intravenous rituximab (375mg/m2) and per-oral tablet 
prednisolone (100mg D1 to D5). Patients with low 
grade disease or who could not receive antracycline for 
cardiac reasons received  rituximab plus CVP or CVP. 
Patients with cerebral lymphoma received intravenous 
high-dose methotrexate (4-8mg/m2). Patients who had 
bulky disease at presentation, partial response or stable 
disease after chemotherapy were treated by involved-
field radiotherapy at a dose of 40 Gy in 20 fractions in 
conventional fractionation over 4 weeks after completion 
of chemotherapy. Patients with localized disease like 
orbital NHL were treated by involved- field radiotherapy 
alone at dose of 44 Gy in 22 fractions in conventional 
fractionation over 4.5 weeks.
The initial therapy and therapeutic response [complete 
response (CR), partial response (PR), progressive disease 
(PD), stable disease (SD)] were accurately documented 
for each case. A CR to treatment was defined by the 
disappearance of all clinical evidence of the disease and 
normalization of all laboratory values and including 
radiography results which were abnormal before 
treatment. Treatment outcome was measured using overall 
survival. It was measured as the interval between the 
beginning of treatment and death or the date of the last 
follow-up evaluation. Patients were usually seen every 3 
months in the first two year, every 6 months in the third 
and fourth years and a year in subsequent years.
Statistical analysis
Data analysis was performed using the SPSS for 
Windows 11.5 program. Descriptive statistical analyses for 
continuous and cross sectional variables were expressed 
as mean±standard deviation, whereas categorical variable 
were expressed as number of cases and percentage. 
Kaplan-Meier survival analysis was used to evaluate the 
statistical significant effect of residential areas on overall 
survival, using the Log-Rank test.
Results 
Primary extranodal NHL, constituted 12.4% (100 / 
802) of all NHL studied during this period. Median age of 
the patients was 56 years (range 17-87 years) and the male: 
female distribution was 3:2. Ten out of 100 patients (10%) 
had B-symptoms (significant fever > 380 C, drenching 
night sweats, and unexplained weight loss exceeding 10% 
of normal body weight within the last 6 months), and 6 out 
of the 100 patients (6%) had elevated serum LDH levels 
(> 450 U/L) at presentation. Percentages of Stage I, II, III 
and IV patients were found as 52,33,9, and 6% in whole 
group, respectively.
Patients were also categorized according to the 
International Prognostic Index (IPI) for aggressive 
lymphoma, and the International Prognostic Index 
(FILIPI) for patients with follicular lymphoma according 
to the description by the International non-Hodgkin’s 
Prognostic Factors Project. Low, low-intermediate, high-
intermediate, and high IPI were found in 76, 19, 4, and 
1% of patients, respectively.
Eighty-five of 100 patients (85%) were in stage I/
II, 9/100 (9%) in stage III, whereas 6/100 (6%) were in 
stage IV. 
Head and neck lymphomas (HNL) constituted the 
most common site of pENL (51/100, 51%), followed by 
gastrointestinal lymphomas (GIL) (37/100, 37%), and 
cerebral lymphomas ( CL) (5/100, 5%). 
Immunohistochemical evaluation demonstrated that 
83% of pENL had B-cell immunophenotype whereas 
T cell phenotype was observed in only 7% of patients. 
Indeed, Diffuse large B cell Lymphoma (DLBCL) was 
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the most common histological type observed in 53% of 
patients.  Marginal zone extranodal lymphoma, follicular 
lymphoma, mantle cell lymphoma, MALToma, non-
specified B-cell Lymphoma and anaplastic large cell 
lymphoma were found in 13, 7,6, 6, 8, and 4 % of patients, 
respectively.   
Chemotherapy was the mainstay of treatment. Out of 
100 patients, 82 (82%) received chemotherapy. Forty-four 
patients received chemotherapy with R-CHOP regimen, 
while nine patients received R-CVP regimen. The CHOP 
regimen (without Rituximab) was given to eight patients. 
In total, 27 out of 100 patients (27%) of pENL required 
invoved-field radiotherapy (IFRT). Four patients were 
treated only by IFRT alone and in the remaining 23 patients 
IFRT was added to chemotherapy. Treatment modalities 
are shown in Table 1.
Ninety-three patients were evaluated for response to 
treatment. Two of these patients refused treatment, three 
patients underwent tonsillectomy due to lymphoma of the 
tonsils, one patient was operated on due to lymphoma of 
the parotid gland, whereas one underwent surgery due to 
orbital lymphoma. No postoperative treatment was given 
to these patients because of the low-grade nature of their 
pathology results. In the remaining 93 patients, after 
induction treatment, CR were achieved in 71 patients, 
PR was achieved in 11 patients, SD was achieved in 2 
patients while PD was achieved in 9 patients. Nineteen 
patients died at the end of the study, whereas 81 patients 
were reported to be alive. Treatment outcome of patients 
according to primary site are shown in Table 2.
The median follow-up duration to the time of 
progression was reported as 8 months (range, 4.5-52 
months), in patients (9%) with progressive disease. The 
median follow-up duration of all patients was reported 
as 37.6 months (range, 0.8-165 months). On the other 
hand, the mean survival duration was found to be 129.5 
months (range, 44.7-114.3 months) for the whole group; 
this period was reported as 137.5 months (range, 117.5-
1578.6 months) in gastrointestinal lymphoma (GIL) 
patients, 119.0 months (range, 91.8-146.1 months) in head 
and neck lymphoma ( HNL) patients, and 18.4 months 
(range, 12.6-24.1 months) in cerebral lymphoma (CL) 
patients. The mean survival duration of the whole group 
and the mean survival duration of patients according to 
site of involvement are shown in the Kaplan-Meier curves 
of Figure 1 and Figure 2.
Discussion
ENL is a heterogeneous disease with regards 
to geographical, ethnic, anatomic, etiological and 
morphological diversities (Anderson et al., 1998). The 
frequency of ENL varies in different part of the world. 
Newton et al. (1997) described the epidemiology and 
geographical distribution of NHL in different countries. 
The authors used site-specific information of NHL from 
thirty-nine cancer centers in fourteen countries. The 
incidence rate for all NHL, combined varied from a low 2 
per 100.000 per year in Thailand to about 10 per 100.000 in 
Caucasians in the USA. Across Europe, there was roughly 
a 2-fold difference observed from about 4 per 100.000 in 
Slovakia to about 8 per 100.000 in the Netherlands.
The total proportion classified as being of extranodal 
origin ranged from to 22-25% of all lymphomas in the 
USA to 33% in Denmark and 34% in Israel. France 
Table 1. Treatment Received by Patients
Treatment modality n=100
CHOP 8%
MTX +RT 3%
R-CHOP 44%
R-CHOP+IFRT 24%
R-CVP 9%
Only IFRT 4%
No treatment 8%
CHOP: Inj. cyclophosphamide (750 mg/m2), inj. doxorubicin (50 mg/m2), 
inj. vincristin (1.4 mg/m2, maximum daily döşe of 2 mg, and per oral tab. 
prednisolone(100 mg D1 to D5), CVP:Inj. cyclophosphamide (750 mg/m2), inj. 
vincristin (1.4 mg/m2, maximum daily döşe 2 mg) and per oral tab. Prednisolone 
(100 mg D1 to D5), MTX: inj. methotraxete (4-6 mg/m2), R: inj. rituximab (375 
mg/m2), IFRT: involved field radiotherapy, RT: radiotherapy
Tablo 2. Treatment Outcome of Patients According to 
Primary Site
Primary Site CR PR SD PD No  Alive Exitus
     treatment  
Gastrointestinal 31 1 2 2 1 31 6
Head and Neck 34 6 -  4 6 43 7
Cerebral 1 2 - 2 - 1 4
Breast 1 - - - - 1 -
Testis -  1 - 1 - - 2
Urinary Bladder 1 - - - -  1 -
Ovarian 1 - - - - 1 -
Lung 1 - - - - 1 - 
ThyroidPericardTotal 1-71 -111 -2 -9 --7 1181 -19
CR:complete response, PR: partial response, SD: stable disease, PD: progressive 
disease
Figure 1. The Mean Survival Duration of the Patients
Figure 2. The Mean Survival Duration of Patients 
According to Site of Involvement
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(42%) and Kuwait (43%) had particularly high relative 
extranodal lymphoma frequencies (Newton et al., 1997). 
Compared to these epidemiological data, results of our 
series is very low (12.4%). This may be explained by 
overall small number of NHL during the study period 
(802 in 10 years), or strict inclusion criteria.
ENL’s may occur in any organ. Previous studies have 
demonstrated that the gastrointestinal tract is the most 
common site of involvement for ELN’s, and its incidence 
is rising throughout the world (Arora et al., 1998). 
However, head and neck region including Waldeyer’s ring, 
nose, and paranasal sinuses, have been reported to be the 
most common sites of origin of  pENL, in various studies 
from different parts of China (Yang et al., 2011), India 
(Singh et al., 2003), and Japan (Fujita et al., 2009). In our 
study, the most common site of ENL was reported for head 
and neck lymphomas (51%), followed by gastrointestinal 
lymphomas (37%). In variety Asian studies (Singh et al., 
2003; Fujita et al., 2009; Chen et al., 2010; Yang et al., 
2011), it has been shown that head and neck lymphoma 
are the most commonly seen forms. This difference was 
explained by environmental pollutants, Epstein- Barr 
virus, agricultural pesticides (Chen et al., 2010), poor oro-
dental hygiene, tobacco chewing (Singh et al., 2003), and 
more predilection of NK/T cell lymphoma phenotypes for 
head and neck region (Vose et al., 2008). 
The pattern of primary GIL in our study was similar 
to the western population as well as two largest studies 
from India. In these two studies, similar to our study, 
the stomach was the most common site of involvement 
and DLBCL was the most common histological subtype, 
whereas, according to another study in Europe (Mihaljevic 
et al., 2006)  MALT lymphoma was accounted for 70% 
of GIL.
In accordance with literature, DLBCL was the most 
common histological subtype observed, both at nodal and 
extranodal sites. DLBCL, follicular lymphoma, anaplastic 
large cell lymphoma (ALCL) and nodal marginal zone 
lymphoma were the four most common subtype at 
nodal site; whereas DLBCL, extranodal marginal zone 
lymphoma of the MALT type, and peripheral T-cell 
lymphoma were most common at extranodal sites (Fujita 
et al., 2009; Yaqo et al., 2011; Yang et al., 2011). According 
to our study, the most common histologic subtypes of ENL 
were DLBCL, extranodal marginal zone lymphoma and 
follicular lymphoma. These results also support those in 
the literature.
The biological behavior of primary ENL has been 
reported to be complex in different studies. Krol et al. 
(Krol et al., 2003) showed that ENL patients had a better 
survival outcome, whereas, Lal et al. (2008) reported that 
nodal and extranodal sites did not have any prognostic 
significance and that the overall survival in both groups 
largely depended on IPI and not on the site of origin of 
malignancy. According to our study, patients with pENL 
had lesser B symptoms, lower serum LDH level, a high 
percentage of low and low-intermediate IPI score (95%) 
and high in the early stage (stage 1 and stage 2, 81%). 
These results probably explained the favorable prognosis 
in our cohort of patients.
In conclusion, according to our study, the incidence 
of pENL in Turkey’s southern region is low, compared 
to data from other parts of the world. Head and neck, 
and the gastrointestinal tract were the two most common 
extranodal sites observed. Histologically DLBC accounted 
for the majority of cases. Most patients were on earlier 
stages, had low-low intermediate IPI scores and had a 
favorable prognosis. Future efforts should focus on genetic 
profile of lymphomas in order to understand the biology 
of this group of tumors.
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